Sumitomo Dainippon Pharma Annual Report 2017
5/102 Pharmaceuticals CEO David J. Bearssexplaining the hematologic malignancies treatment pipeline at an R&D meetingThe acquisition of Cynapsus Therapeutics Inc. (Canada) added to our pipeline sublingual apomorphine hydrochloride, under development as a treatment for OFF episodes associated with Parkinson’s disease, and the acquisition of Tolero Pharmaceuticals, Inc. (U.S.) added alvocidib, under development as a hematologic malignancies treatment. We aim to bring these compounds to market in fiscal 2018–2019.Additionally, Sunovion Pharmaceuticals Inc. entered into an exclusive license agreement with Novartis for the U.S. commercialization rights to three treatments for chronic obstructive pulmonary disease (COPD).Enhancedpipeline from acquisitionsand in-licensingLATUDA®, which grew into a blockbuster drug surpassing annual sales of US$ 1 billion in North America in fiscal 2015, continued to post strong results in fiscal 2016, recording sales of US$ 1.25 billion. This was a new record high for sales.LATUDA® sets anew recordfor North American sales04Sumitomo Dainippon Pharma Co., Ltd. Annual Report 2017

元のページ  ../index.html#5